Pricing and reimbursement of drugs in Sweden

被引:9
|
作者
Lundkvist J. [1 ,2 ]
机构
[1] Stockholm HealthEconomics Consulting, Uppsala
[2] Stockholm HealthEconomics Consulting, 75318 Uppsala
关键词
Drug cost; Health care systems; Pricing; Reimbursement;
D O I
10.1007/s10198-001-0094-1
中图分类号
学科分类号
摘要
The Swedish public health care system is financed mainly by taxes. The major part of drug costs is paid by the drug reimbursement system. Sweden has, as most other countries, seen a large increase in the expenditures on drugs in recent years. The responsibility for the cost of drugs in Sweden has recently been decentralized to the county council level. The reimbursement system of drugs currently covers all drugs with a price approved by the National Social Insurance Board, unless the government specifically decides against such coverage. Two groups of drugs were recently excluded from coverage: drugs for obesity and impotence. The price level of drugs in Sweden is close to the average of the European countries. Economic evaluations are currently not mandatory in Swedish price and reimbursement negotiations but are nonetheless important, particularly in negotiations for drugs expected to command large price premiums. The Swedish pricing and reimbursement system has recently been under investigation, and new reforms are expected in the near future. © Springer-Verlag 2002.
引用
收藏
页码:66 / 67
页数:1
相关论文
共 50 条
  • [21] Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?
    Oliva-Moreno, Juan
    Puig-Junoy, Jaume
    Trapero-Bertran, Marta
    Epstein, David
    Pinyol, Carme
    Antonio Sacristan, Jose
    VALUE IN HEALTH, 2020, 23 (01) : 25 - 31
  • [22] EVIDENCE REQUIREMENTS FOR PRICING AND REIMBURSEMENT DECISION MAKING FOR ORPHAN DRUGS IN ASIA
    Tan, S.
    Dummett, H.
    Kirpekar, S.
    Guan, Q.
    Priest, V. L.
    VALUE IN HEALTH, 2012, 15 (07) : A621 - A622
  • [23] THE PRICING AND REIMBURSEMENT OF PHARMACEUTICALS
    TOWSE, A
    PHARMACOECONOMICS, 1994, 6 : 36 - 38
  • [24] Pharmaceutical Pricing and Reimbursement in Japan: For Faster, More Complete Access to New Drugs
    Akane Takayama
    Mamoru Narukawa
    Therapeutic Innovation & Regulatory Science, 2016, 50 : 361 - 367
  • [25] Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis
    Garattini, Livio
    Cornago, Dante
    De Compadri, Paola
    HEALTH POLICY, 2007, 82 (03) : 330 - 339
  • [27] REIMBURSEMENT AND VALUE PRICING
    BURRILL, GS
    THOMPSON, K
    BIOPHARM-THE TECHNOLOGY & BUSINESS OF BIOPHARMACEUTICALS, 1991, 4 (02): : 36 - 38
  • [28] Pharmaceutical Pricing and Reimbursement in Japan: For Faster, More Complete Access to New Drugs
    Takayama, Akane
    Narukawa, Mamoru
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (03) : 361 - 367
  • [29] A comparative analysis of the financing, pricing and reimbursement systems for prescription drugs in the Nordic countries
    Kristensen, FKO
    Sverre, JM
    Holm, LB
    VALUE IN HEALTH, 2005, 8 (06) : A188 - A188
  • [30] CURRENT CHALLENGES AND POTENTIAL SOLUTION FOR PRICING REGULATORY AND REIMBURSEMENT FRAMEWORK OF INNOVATIVE DRUGS IN EGYPT
    ElMordy, B.
    Fouad, S.
    Elsisi, G. H.
    Elmahdawy, M. D.
    VALUE IN HEALTH, 2018, 21 : S174 - S174